Key result
Dendropanax morbifera extract significantly improved the viability of hypoxia/reoxygenation-injured cardiomyocytes to 87.7% compared to 56.3% in the non-treated group.
Why the study?
The effect of extract from Dendropanax morbifera on myocardial ischemic injury remained unknown.
Population
Neonatal rat cardiomyocytes with hypoxia/reoxygenation injury
Comparison
EDM vs untreated hypoxia/reoxygenation-injured positive control
Design
In vitro experimental study
Authors
Loading...
Hypothesis-generating for natural-product cardioprotection; requires in vivo and clinical validation before any practice consideration.
Absolute Event Rate: 87.7% vs 56.3%
p-value: p=<0.05
Dendropanax morbifera extract protects neonatal rat cardiomyocytes from hypoxia/reoxygenation injury in vitro by reducing reactive oxygen species generation and preserving calcium homeostasis.
Lim et al. (2019) studied Hypoxia/reoxygenation injury. Dendropanax morbifera extract (EDM) vs. Non-treated H/R-injured cardiomyocytes was evaluated on Cell viability (p=<0.05). Dendropanax morbifera extract significantly improved the viability of hypoxia/reoxygenation-injured cardiomyocytes to 87.7% compared to 56.3% in the non-treated group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: